Mucuna pruriens

The outcomes below are the ones Mucuna products are marketed for. Each grade covers one outcome, and the evidence grading method explains what each grade requires. For other compounds studied for these goals, see the mood and stress and focus hubs.

Does mucuna pruriens reduce stress?

The evidence is one small study in a clinical group [7]. Researchers enrolled 60 men undergoing infertility screening who had psychological stress, judged by a questionnaire and raised blood cortisol [7]. They received 5 g/day of Mucuna seed powder by mouth for 3 months, and the authors reported that psychological stress improved along with sperm count and motility [7]. The study was funded by the Indian Council of Medical Research [7].

There was no placebo group and no untreated group of stressed men [7]. The 60 controls were healthy fertile men, not stressed men, so they are not a comparison for the effect of Mucuna on stress [7]. Without a placebo, a drop in self-rated stress over 3 months cannot be separated from expectation or from time passing.

Overlapping authors ran two related studies [7][8][9] in men undergoing infertility screening, one in 75 men measuring hormones, which reported higher testosterone and lower prolactin after treatment [8], and one in 60 men measuring semen chemistry [9]. Neither measured stress as an outcome, and both used the same before-and-after design [8][9]. This is a clinical population, and results may not apply to healthy adults.

Does mucuna pruriens improve mood?

We found no placebo-controlled trials of Mucuna on mood in people (PubMed and Europe PMC searches, November 11, 2026). A 2024 review of Mucuna and mood-related research drew its evidence from animal models and concluded that clinical trials are needed [15]. As of November 11, 2026 we found no randomized trials of Mucuna on mood in healthy adults (PubMed and Europe PMC searches, November 11, 2026).

Parkinson's disease trials did score non-motor symptoms [3][4]. In a 12-month randomized open-label trial in 32 untreated people with Parkinson's disease in sub-Saharan Africa, Mucuna powder and standard levodopa with a decarboxylase inhibitor gave similar results on quality of life, motor and non-motor symptoms [4]. That trial compared Mucuna with an active medicine, not with placebo, in a clinical population, so it does not test whether Mucuna changes mood in healthy adults [4].

Does mucuna pruriens increase motivation?

No human study of Mucuna that we found measured motivation. Some US products carry label wording such as "supports dopamine production and motivation" [10]. As of November 11, 2026 we found no controlled human study of Mucuna that measured motivation (PubMed and Europe PMC searches, November 11, 2026). Levodopa content explains why the idea exists, but a mechanism is not evidence of an effect.

Does mucuna pruriens help focus or attention?

No study we found tested Mucuna alone on attention. As of November 11, 2026 we found no controlled study of Mucuna alone that measured attention or other cognitive tests in healthy adults (PubMed and Europe PMC searches, November 11, 2026). We set aside one trial of a multi-ingredient pre-workout product because the effect of Mucuna could not be separated from the other ingredients. L-tyrosine is an amino acid precursor of levodopa [12], and the L-tyrosine page grades its own evidence separately.

What the evidence does not show

The human effects of Mucuna measured most often are on movement symptoms in Parkinson's disease, and they come from small trials in a clinical population [6]. A 2025 systematic review found 5 clinical trials with 108 participants (mean age 60), rated one high quality, one with some concerns and three low quality, and concluded that the clinical evidence is limited [6]. These trials compared Mucuna with prescription levodopa and say nothing about healthy adults.

In a randomized, controlled, double-blind crossover trial in 8 people with Parkinson's disease, a single 30 g dose of Mucuna preparation acted faster than a standard levodopa/carbidopa tablet (34.6 v 68.5 minutes) [1]. In a double-blind, randomized, controlled crossover trial in 18 people with advanced Parkinson's disease, the clinical effects of high-dose Mucuna were similar to levodopa alone at the same levodopa dose [2]. Both trials were small. Results may not apply to healthy adults, and the published abstracts of these trials report no stress, mood, motivation or attention outcomes [1][2][5].

The forms used in trials are powder from roasted seeds [2][3][4] and seed preparations [1]. Commercial products often contain seed extracts, which can hold much more levodopa than seeds [11].

A randomized, single-blind crossover trial recruited 12 people with Parkinson's disease and analyzed 11 after one withdrawal [5]. In that trial, 30 g of Mucuna powder produced higher total levodopa exposure than two 100/25 levodopa/benserazide tablets, with a geometric mean ratio of 155.67% (90% CI 134.59-180.04) [5]. Time to peak level and half-life were similar for the two [5]. In the 2004 trial, peak levodopa levels were 110% higher and total exposure 165.3% larger with 30 g of Mucuna than with standard levodopa/carbidopa [1]. Without a decarboxylase inhibitor, a commercial extract gave much lower blood levodopa in a two-patient study [16]. The levodopa label notes that a high-protein diet may impair levodopa absorption in some patients [23].

Safety data come mainly from small trials in people with Parkinson's disease, plus regulator advice [3][4][22]. As of November 11, 2026 we found no LiverTox chapter and no NIH ODS fact sheet for Mucuna pruriens (NCBI Books and ODS list searches, November 11, 2026).

Tolerability is the clearest signal [3]. In a 16-week randomized crossover pilot in 14 people with advanced Parkinson's disease, 7 (50%) stopped Mucuna early because of gastrointestinal side effects (4) or worsening movement (3), while nobody stopped during the levodopa/carbidopa phase [3]. In the 12-month trial, adverse events were more frequent with Mucuna (56% vs. 37.5%), but the difference was not statistically significant, most were mild and 12.5% led to stopping [4]. Mild, transient adverse events such as nausea and dizziness were more common with Mucuna in the 2025 crossover trial [5]. In the 8-person 2004 single-dose trial, the authors found no statistically significant difference in dyskinesia (involuntary movement) between Mucuna and standard levodopa/carbidopa [1]. The 18-person 2017 single-dose trial reported fewer dyskinesias with high-dose Mucuna than with levodopa/benserazide [2].

RIVM, the Dutch public health institute, assessed Mucuna supplements for the Netherlands' health ministry [22]. It says very little scientific information is available, so a safe dose cannot be set, and that there are indications of negative effects on the liver, kidneys and the development of unborn children [22]. RIVM says levodopa side effects, such as gastrointestinal symptoms, involuntary movement and psychological symptoms, can also occur with Mucuna supplements, and advises stopping if side effects appear [22].

A 2026 review by two Mucuna trial investigators says Mucuna is a potent dopaminergic therapy that needs the same caution as levodopa medicines [14]. They report that overuse and unsupervised self-medication have been linked to dyskinesia, dopamine dysregulation syndrome and psychiatric complications, and that improper seed preparation has caused toxicity [14]. Long-term safety data are still scarce [14].

Product quality is a safety issue here [10][11][12]. No product in one test of six fell within the 90%-110% pharmacopeial range for its label claim [11]. In a 2026 analysis of 5 preparations, levodopa was 66.2% to 82.7% of the amount manufacturers reported [12]. In the analysis of 16 US supplements, measured levodopa was 228% to 2186% greater than the amount estimated from the label [10].

We found no interaction study of Mucuna itself (PubMed search, November 11, 2026). Because Mucuna seeds and supplements deliver levodopa [1][10], the interactions on prescription levodopa labels are the relevant reference [23]. RIVM advises that people who use medicines consult a doctor or pharmacist before using Mucuna supplements [22].

The FDA-approved carbidopa and levodopa label reports the following [23]:

• Monoamine oxidase (MAO) inhibitors: nonselective MAO inhibitors are contraindicated with levodopa and must be stopped at least two weeks before starting it [23]. The label says selegiline taken with carbidopa and levodopa may be associated with severe orthostatic hypotension (a drop in blood pressure on standing) [23].
• Medicines that lower blood pressure: symptomatic postural hypotension occurred when levodopa was added to antihypertensive drugs [23].
• Tricyclic antidepressants: rare reports of high blood pressure and dyskinesia [23].
• Dopamine D2 receptor blockers, such as risperidone, and isoniazid: these may reduce the effects of levodopa [23].
• Iron salts: these can bind levodopa and reduce how much is absorbed [23].

Prescription levodopa medicines are a separate concern: Mucuna adds levodopa, and the 2026 review links unsupervised use to dyskinesia and dopamine dysregulation syndrome [14]. Two patients in a case study were taking self-prescribed Mucuna on top of standard levodopa [16].

If you take any of these medicines, talk to your doctor or pharmacist before combining them with mucuna pruriens.